Future experiments could examine expression of various APP metabolites on neurogenesis, compare BACE-1 and mGluR5 inhibitors, confirm FXS signaling pathways in this early disease-stage model, and transfect plasmids carrying varying length CGG repeats in the human FMR1 gene to mimic the repeat expansion aspect of the disorder. The gene discussed is APP; the disease is fragile X syndrome.